Selected research
Industry Research
Female Contraceptives Industry Research Report 2026
Market perspective
The global Female Contraceptives market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Female Contraceptives market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Female Contraceptives market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Female Contraceptives market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Female Contraceptives include Teva, Johnson & Johnson, Merck, Mylan, Pfizer, Bayer, Mayer Laboratories, Lupin Pharmaceuticals and Fuji Latex and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Female Contraceptives market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Female Contraceptives.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Female Contraceptives Market by Company
Teva
Johnson & Johnson
Merck
Mylan
Pfizer
Bayer
Mayer Laboratories
Lupin Pharmaceuticals
Fuji Latex
Female Health Company
Female Contraceptives Segment by Type
Female Contraceptive Devices
Female Contraceptive Drugs
Female Contraceptives Segment by Application
Online Stores
Retail Outlets
Female Contraceptives Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Female Contraceptives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Female Contraceptives and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Female Contraceptives.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Female Contraceptives companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Female Contraceptive Devices
- Female Contraceptive Drugs
Applications
- Online Stores
- Retail Outlets
Companies covered
- Teva
- Johnson & Johnson
- Merck
- Mylan
- Pfizer
- Bayer
- Mayer Laboratories
- Lupin Pharmaceuticals
- Fuji Latex
- Female Health Company
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Female Contraceptives by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Female Contraceptive Devices
- 2.2.3 Female Contraceptive Drugs
- 2.3 Female Contraceptives by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Online Stores
- 2.3.3 Retail Outlets
- 2.4 Assumptions and Limitations
3 Female Contraceptives Breakdown Data by Type
- 3.1 Global Female Contraceptives Historic Market Size by Type (2021-2026)
- 3.2 Global Female Contraceptives Forecasted Market Size by Type (2027-2032)
4 Female Contraceptives Breakdown Data by Application
- 4.1 Global Female Contraceptives Historic Market Size by Application (2021-2026)
- 4.2 Global Female Contraceptives Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Female Contraceptives Market Perspective (2021-2032)
- 5.2 Global Female Contraceptives Growth Trends by Region
- 5.2.1 Global Female Contraceptives Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Female Contraceptives Historic Market Size by Region (2021-2026)
- 5.2.3 Female Contraceptives Forecasted Market Size by Region (2027-2032)
- 5.3 Female Contraceptives Market Dynamics
- 5.3.1 Female Contraceptives Industry Trends
- 5.3.2 Female Contraceptives Market Drivers
- 5.3.3 Female Contraceptives Market Challenges
- 5.3.4 Female Contraceptives Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Female Contraceptives Players by Revenue
- 6.1.1 Global Top Female Contraceptives Players by Revenue (2021-2026)
- 6.1.2 Global Female Contraceptives Revenue Market Share by Players (2021-2026)
- 6.2 Global Female Contraceptives Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Female Contraceptives Head Office and Area Served
- 6.4 Global Female Contraceptives Players, Product Type & Application
- 6.5 Global Female Contraceptives Manufacturers Established Date
- 6.6 Global Female Contraceptives Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Female Contraceptives Market Size (2021-2032)
- 7.2 North America Female Contraceptives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Female Contraceptives Market Size by Country (2021-2026)
- 7.4 North America Female Contraceptives Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Female Contraceptives Market Size (2021-2032)
- 8.2 Europe Female Contraceptives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Female Contraceptives Market Size by Country (2021-2026)
- 8.4 Europe Female Contraceptives Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Female Contraceptives Market Size (2021-2032)
- 9.2 Asia-Pacific Female Contraceptives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Female Contraceptives Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Female Contraceptives Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Female Contraceptives Market Size (2021-2032)
- 10.2 South America Female Contraceptives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Female Contraceptives Market Size by Country (2021-2026)
- 10.4 South America Female Contraceptives Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Female Contraceptives Market Size (2021-2032)
- 11.2 Middle East & Africa Female Contraceptives Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Female Contraceptives Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Female Contraceptives Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Female Contraceptives Business (2021-2026)
- 12.1.4 Teva Female Contraceptives Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Female Contraceptives Business (2021-2026)
- 12.2.4 Johnson & Johnson Female Contraceptives Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in Female Contraceptives Business (2021-2026)
- 12.3.4 Merck Female Contraceptives Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 Mylan
- 12.4.1 Mylan Company Information
- 12.4.2 Mylan Business Overview
- 12.4.3 Mylan Revenue in Female Contraceptives Business (2021-2026)
- 12.4.4 Mylan Female Contraceptives Product Portfolio
- 12.4.5 Mylan Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Female Contraceptives Business (2021-2026)
- 12.5.4 Pfizer Female Contraceptives Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Bayer
- 12.6.1 Bayer Company Information
- 12.6.2 Bayer Business Overview
- 12.6.3 Bayer Revenue in Female Contraceptives Business (2021-2026)
- 12.6.4 Bayer Female Contraceptives Product Portfolio
- 12.6.5 Bayer Recent Developments
- 12.7 Mayer Laboratories
- 12.7.1 Mayer Laboratories Company Information
- 12.7.2 Mayer Laboratories Business Overview
- 12.7.3 Mayer Laboratories Revenue in Female Contraceptives Business (2021-2026)
- 12.7.4 Mayer Laboratories Female Contraceptives Product Portfolio
- 12.7.5 Mayer Laboratories Recent Developments
- 12.8 Lupin Pharmaceuticals
- 12.8.1 Lupin Pharmaceuticals Company Information
- 12.8.2 Lupin Pharmaceuticals Business Overview
- 12.8.3 Lupin Pharmaceuticals Revenue in Female Contraceptives Business (2021-2026)
- 12.8.4 Lupin Pharmaceuticals Female Contraceptives Product Portfolio
- 12.8.5 Lupin Pharmaceuticals Recent Developments
- 12.9 Fuji Latex
- 12.9.1 Fuji Latex Company Information
- 12.9.2 Fuji Latex Business Overview
- 12.9.3 Fuji Latex Revenue in Female Contraceptives Business (2021-2026)
- 12.9.4 Fuji Latex Female Contraceptives Product Portfolio
- 12.9.5 Fuji Latex Recent Developments
- 12.10 Female Health Company
- 12.10.1 Female Health Company Company Information
- 12.10.2 Female Health Company Business Overview
- 12.10.3 Female Health Company Revenue in Female Contraceptives Business (2021-2026)
- 12.10.4 Female Health Company Female Contraceptives Product Portfolio
- 12.10.5 Female Health Company Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst